A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated 136 enrolled Criterium, Inc. Amgen · collab Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.

Timeline

Start: 2011-11
Primary completion: 2020-07
Completion: 2020-07

Outcome

Outcome not reported

Stopped (Enrollment): “Lack of enrollment”

Publications

Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320. Epub 2015 Sep 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carfilzomib	Other / unclassified	27 mg/m2	Intravenous
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Pomalidomide	Other / unclassified	4 mg	Oral